Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison.

Metabolite profiling of tissue samples is a promising approach for the characterization of cancer pathways and tumor classification based on metabolic features. Here, we present an analytical method for nontargeted metabolomics of kidney tissue. Capitalizing on different chemical properties of metabolites allowed us to extract a broad range of molecules covering small polar molecules and less polar lipid classes that were analyzed by LC-QTOF-MS after HILIC and RP chromatographic separation, respectively. More than 1000 features could be reproducibly extracted and analyzed (CV < 30%) in porcine and human kidney tissue, which were used as surrogate matrices for method development. To further assess assay performance, cross-validation of the nontargeted metabolomics platform to a targeted metabolomics approach was carried out. Strikingly, from 102 metabolites that could be detected on both platforms, the majority (>90%) revealed Spearman's correlation coefficients ≥0.3, indicating that quantitative results from the nontargeted assay are largely comparable to data derived from classical targeted assays. Finally, as proof of concept, the method was applied to human kidney tissue where a clear differentiation between kidney cancer and nontumorous material could be demonstrated on the basis of unsupervised statistical analysis.

[1]  Cristina Bianchi,et al.  Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. , 2015, Cancer research.

[2]  Xin Lu,et al.  Multiple reaction monitoring-ion pair finder: a systematic approach to transform nontargeted mode to pseudotargeted mode for metabolomics study based on liquid chromatography-mass spectrometry. , 2015, Analytical chemistry.

[3]  Anthony B. Costa,et al.  Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry , 2010, Analytical and bioanalytical chemistry.

[4]  Otto Savolainen,et al.  A Simultaneous Metabolic Profiling and Quantitative Multimetabolite Metabolomic Method for Human Plasma Using Gas-Chromatography Tandem Mass Spectrometry. , 2016, Journal of proteome research.

[5]  M. Schwab,et al.  DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome , 2013, Clinical Cancer Research.

[6]  Caroline H. Johnson,et al.  Metabolomics: beyond biomarkers and towards mechanisms , 2016, Nature Reviews Molecular Cell Biology.

[7]  Xiaomei Yan,et al.  Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. , 2010, The Analyst.

[8]  Joachim Selbig,et al.  Metabolic profiling reveals key metabolic features of renal cell carcinoma , 2009, Journal of cellular and molecular medicine.

[9]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[10]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[11]  Arndt Hartmann,et al.  Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. , 2015, European urology.

[12]  Oliver Fiehn,et al.  Pathway analysis of kidney cancer using proteomics and metabolic profiling , 2006, Molecular Cancer.

[13]  T. Spector,et al.  Genetic Influences on Metabolite Levels: A Comparison across Metabolomic Platforms , 2016, PloS one.

[14]  Chris Sander,et al.  An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.

[15]  A. Davies,et al.  Untargeted UPLC-MS Profiling Pipeline to Expand Tissue Metabolome Coverage: Application to Cardiovascular Disease , 2015, Analytical chemistry.

[16]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[17]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[18]  R. Murphy,et al.  Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids , 2004, Journal of the American Society for Mass Spectrometry.

[19]  Xiaomei Yan,et al.  LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. , 2011, Journal of proteome research.

[20]  U. Hofmann,et al.  Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor , 2015, Analytical and Bioanalytical Chemistry.

[21]  M. Snyder,et al.  Can Metabolic Profiles Be Used as a Phenotypic Readout of the Genome to Enhance Precision Medicine? , 2016, Clinical chemistry.

[22]  Oliver Fiehn,et al.  Toward Merging Untargeted and Targeted Methods in Mass Spectrometry-Based Metabolomics and Lipidomics. , 2016, Analytical chemistry.

[23]  M. Haag,et al.  Quantification of Signaling Lipids by Nano-Electrospray Ionization Tandem Mass Spectrometry (Nano-ESI MS/MS) , 2012, Metabolites.

[24]  Ralf Tautenhahn,et al.  Toward 'omic scale metabolite profiling: a dual separation-mass spectrometry approach for coverage of lipid and central carbon metabolism. , 2013, Analytical chemistry.

[25]  H. Fujii,et al.  Analysis of Renal Cell Carcinoma as a First Step for Developing Mass Spectrometry-Based Diagnostics , 2012, Journal of The American Society for Mass Spectrometry.

[26]  M. Barrett,et al.  Enhanced Acylcarnitine Annotation in High-Resolution Mass Spectrometry Data: Fragmentation Analysis for the Classification and Annotation of Acylcarnitines , 2015, Front. Bioeng. Biotechnol..

[27]  M. T. Donato,et al.  A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. , 2011, Journal of proteome research.

[28]  M. Hirai,et al.  MassBank: a public repository for sharing mass spectral data for life sciences. , 2010, Journal of mass spectrometry : JMS.

[29]  R. Murphy,et al.  Detection of the abundance of diacylglycerol and triacylglycerol molecular species in cells using neutral loss mass spectrometry. , 2007, Analytical biochemistry.

[30]  Xin Lu,et al.  Optimization of large-scale pseudotargeted metabolomics method based on liquid chromatography-mass spectrometry. , 2016, Journal of chromatography. A.

[31]  C. Barbas,et al.  Rapid and Reliable Identification of Phospholipids for Untargeted Metabolomics with LC-ESI-QTOF-MS/MS. , 2015, Journal of proteome research.

[32]  Lihua Jiang,et al.  Optimized Analytical Procedures for the Untargeted Metabolomic Profiling of Human Urine and Plasma by Combining Hydrophilic Interaction (HILIC) and Reverse-Phase Liquid Chromatography (RPLC)–Mass Spectrometry* , 2015, Molecular & Cellular Proteomics.

[33]  Yiran Huang,et al.  Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. , 2008, Analytica chimica acta.

[34]  J. Peter-Katalinic,et al.  On-line nano-HPLC/ESI QTOF MS monitoring of α2–3 and α2–6 sialylation in granulocyte glycosphingolipidome , 2009, Biological chemistry.

[35]  M. Carvalho,et al.  Biomarkers in renal cell carcinoma: a metabolomics approach , 2014, Metabolomics.

[36]  Antonio Lopez-Beltran,et al.  Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.

[37]  T. Ebbels,et al.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.

[38]  K. Yamaguchi,et al.  Plasma Membrane-associated Sialidase Is Up-regulated in Renal Cell Carcinoma and Promotes Interleukin-6-induced Apoptosis Suppression and Cell Motility* , 2006, Journal of Biological Chemistry.

[39]  K. Michalak,et al.  Key Roles of Glutamine Pathways in Reprogramming the Cancer Metabolism , 2015, Oxidative medicine and cellular longevity.

[40]  I. Wilson,et al.  A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. , 2006, The Analyst.

[41]  Jerzy Adamski,et al.  Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics , 2011, Metabolomics.

[42]  M. Perazella,et al.  The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. , 2016, Journal of the American Society of Nephrology : JASN.

[43]  T. Ebbels,et al.  Optimization and evaluation of metabolite extraction protocols for untargeted metabolic profiling of liver samples by UPLC-MS. , 2010, Analytical chemistry.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[45]  Taka-Aki Sato,et al.  Structural characterization of neutral glycosphingolipids using high-performance liquid chromatography-electrospray ionization mass spectrometry with a repeated high-speed polarity and MSn switching system , 2013, Glycoconjugate Journal.

[46]  Sejong Bae,et al.  A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody , 2014 .

[47]  Oliver Fiehn,et al.  A comprehensive urinary metabolomic approach for identifying kidney cancerr. , 2007, Analytical biochemistry.

[48]  Christian Gieger,et al.  Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting , 2010, PloS one.

[49]  Y. Kanai,et al.  Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma , 2016, Scientific Reports.

[50]  R. Abagyan,et al.  METLIN: A Metabolite Mass Spectral Database , 2005, Therapeutic drug monitoring.

[51]  David S. Wishart,et al.  MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..

[52]  Tomasz Burzykowski,et al.  Evaluation of normalization methods to pave the way towards large-scale LC-MS-based metabolomics profiling experiments. , 2013, Omics : a journal of integrative biology.

[53]  J. Borén,et al.  Increased Expression of the Very Low-Density Lipoprotein Receptor Mediates Lipid Accumulation in Clear-Cell Renal Cell Carcinoma , 2012, PloS one.

[54]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[55]  E. Mikros,et al.  (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. , 2010, Journal of proteome research.

[56]  Eoin Fahy,et al.  LIPID MAPS online tools for lipid research , 2007, Nucleic Acids Res..

[57]  M. Schwab,et al.  Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. , 2013, Trends in pharmacological sciences.

[58]  R. Weiss,et al.  Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. , 2011, Omics : a journal of integrative biology.

[59]  Kyoungmi Kim,et al.  Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery*S , 2009, Molecular & Cellular Proteomics.

[60]  Julie Klein,et al.  Assessment of Metabolomic and Proteomic Biomarkers in Detection and Prognosis of Progression of Renal Function in Chronic Kidney Disease , 2014, PloS one.

[61]  B. Melichar,et al.  Lipidomic differentiation between human kidney tumors and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data analysis. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[62]  Yiran Huang,et al.  Application of ex vivo 1H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases , 2012, Journal of Cancer Research and Clinical Oncology.